The new National Health Insurance Drug Catalog will open on March 1st with 119 new drugs shortlisted

The results of the new version of the National Health Insurance Directory adjustment, through which 119 new drugs were shortlisted, including 96 exclusive drugs and 23 non-exclusive drugs;
the largest number of drugs negotiated for price reductions in 2020 compared with previous years, and the widest range of therapeutic areas.
162 exclusive drugs were negotiated in the United States, and 119 drugs were successfully negotiated.
prices for drugs negotiated in the united States have been reduced by an average of 50.64 per cent.
28 December 2020, the State Health Insurance Administration and the Ministry of Human Resources and Social Security issued a notice on the National List of Medicines for Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance (2020).
new catalogue will be officially launched nationwide from March 1, 2021.
expected to reduce the burden on patients by about 28 billion yuan by 2021 last August, and the 2020 National Health Insurance Drug Catalog Adjustment Work Programme was issued.
162 exclusive medicines were negotiated in the United States and 119 were successful.
through this catalog adjustment, a total of 119 new drugs into the catalog, and another 29 original catalog drugs were transferred out of the catalog.
total number of medicines in the Revised National List of Essential Medical Insurance, Industrial Injury Insurance and Maternity Insurance (2020) is 2,800, of which 1,426 are Western medicines and 1,374 are Chinese medicines.
chinese medicine tablets in the catalogue were not adjusted and remained at 892.
New Crown Pneumonia treatment-related drugs such as Libawelin injection, Abidor particles and other drugs into the catalog, the latest version of the national new crown pneumonia diagnosis and treatment program listed drugs have been fully included in the national health insurance directory, to help the new crown pneumonia epidemic prevention and control.
some innovative drugs, new drugs such as anti-cancer drugs in the field of immunotherapy drugs, such as negotiated price cuts into health insurance.
new drugs, which were introduced before August 17 last year, were included in the adjustment, and eventually 16 drugs were included in the catalogue.
this adjustment, a lot of children's medication has been added.
The new children's drug specifications and dosage forms are more in line with the characteristics of children, are oral fluids, particles, the dosage is also clearly defined, but also clinically commonly used respiratory and digestive system medication, improve the level of children's medical security.
price cuts and the transfer of catalogs will make room for health-care funds.
's new 119 drugs (96 exclusive, 23 non-exclusive), most of which are negotiated to reduce prices, are expected to increase fund spending by 2021, about the same amount as the space available to negotiate and transfer drugs.
to negotiate price cuts and medicare reimbursements, it is expected to reduce the burden on patients by about 28 billion yuan by 2021.
29 drugs were listed, mainly of low clinical value and replaceable, or by the drug regulatory department to withdraw the number of varieties.
the transfer of these drugs have been repeatedly demonstrated by experts, strictly in accordance with the procedures.
50.64 percent of the 119 successful drug negotiations in 2020 is the third consecutive year that the National Health Insurance Administration has conducted negotiations on access to medicare catalog drugs.
the largest number of drugs negotiated for price reductions in 2020 compared with previous years, and the widest range of therapeutic areas.
162 exclusive drugs were negotiated in the United States.
after negotiations, 119 drugs were successfully negotiated.
success rate of the negotiations was 73.46 per cent.
prices for drugs negotiated in the united States have been reduced by an average of 50.64 per cent.
involved 31 clinical groups, accounting for 86% of all clinical groups.
Huang Bin, vice president of AstraZeneta China, which has participated in the national health care negotiations for four consecutive years, said: "In the 2020 health care catalog adjustment work, the speed of access to innovative drugs has accelerated significantly, the evaluation process has become more scientific, fair and transparent, improving patient access to innovative drugs, and achieving win-win results for patients, enterprises and health insurance."
2020 is also the first attempt to reduce the price of drugs in the catalog negotiations, the price or cost of high, the fund occupies more than 14 exclusive drugs price negotiations, these drugs each drug sales amount of more than 1 billion yuan.
, all 14 drugs were successfully negotiated and kept in the catalogue, with an average price reduction of 43.46 per cent.
the inclusion of unnegotiable varieties in the catalogue into the negotiations is conducive to improving the economy and fairness of the drugs, guiding the return of the standard of payment of drugs in the original catalogue to reasonable, reducing the burden on patients and saving the fund expenditure.
Xiong Xianjun, director of the medical service management department of the National Health Insurance Administration, said that the State Health Insurance Administration to play the advantages of the purchase of medical insurance strategy, make full use of drug access can be "quantity for price" market mechanism, on the basis of scientific evaluation, measurement, negotiations with enterprises, from "passive pay" gradually to "active bargaining", greatly reducing the burden of insured patients, while the structure of the medical insurance drug catalog has been optimized and upgraded.
new 17 anti-cancer drugs 14 kinds of anti-cancer drugs in the catalog to renew the new version of the catalog added 17 new anti-cancer drugs, including new drugs such as lenphatini.
The 14 exclusive drugs in the 2018 special access negotiations for cancer drugs were renewed or renegotied in accordance with the rules, with an average decrease of 14.95 percent, with individual first-line anti-cancer drugs falling by more than 60 percent and the level of protection for cancer drugs in the catalogue significantly increased.
Shi Yuankai, deputy director of the National Cancer Center and vice president of the Oncology Hospital of the Chinese Academy of Medical Sciences, said that the new cancer drugs added in 2020 are the mainstream drugs that have been introduced in the past two years, have clear clinical adaptations, and basically cover cancers in major organs.
common lung cancer, breast cancer drugs increased, some unusual tumors also have drugs that can be used, medication has more options.
the original drug price reduction, accessability greatly improved, to ensure the patient's therapeutic effect.
will be officially launched nationwide from March 1, 2021.
17 cancer drugs that will be accessed through special cancer negotiations in 2018 will be reimbursed under the original policy until February 28, 2021.
the next step, the State Health Insurance Administration will issue documents to guide the local government to do a good job in the implementation of the new version of the catalog landing, do a good job of policy convergence, supporting and information system debugging, guide designated medical institutions to do the necessary preparations as needed.